In agreement with this idea, Torrinhas et al. suggested the immune modulatory properties of n-3 PUFAs will provide important and beneficial effects to improve clinical outcomes of COVID-19 particularly in hospitalized high-risk populations with severe underlying conditions including the elderly, obese, hypertensive, oncologic and diabetic patients (Torrinhas, Calder, & Waitzberg, 2020).